ANIX (Anixa Biosciences) Inventory Turnover: 0.00 (As of Apr. 2026)


ANIX Anixa Biosciences Inc ANIX
27 GF Score
Price $2.81
! 3 Warning Signs
View Full Analysis

What is Anixa Biosciences Inventory Turnover?

Anixa Biosciences ANIX -1.56% 27 Inventory Turnover is 0.00 as of Apr. 2026. GuruFocus rates ANIX with a GF Score™ of 27/100. The stock has 3 warning signs investors should review.

Inventory Turnover measures how fast the company turns over its inventory within a year. It is calculated as Cost of Goods Sold divided by Total Inventories. Anixa Biosciences's Cost of Goods Sold for the three months ended in Apr. 2026 was $0.00 Mil. Anixa Biosciences's Average Total Inventories for the quarter that ended in Apr. 2026 was $0.00 Mil.

Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.


Anixa Biosciences  (NAS:ANIX) Inventory Turnover Explanation

Inventory Turnover measures how fast the company turns over its inventory within a year. A higher Inventory Turnover means the company has light inventory. Therefore the company spends less money on storage, write downs, and obsolete inventory. If the inventory is too light, it may affect sales because the company may not have enough to meet demand.

1. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Anixa Biosciences's Days Inventory for the three months ended in Apr. 2026 is calculated as:

Days Inventory =Average Total Inventories (Q: Apr. 2026 )/Cost of Goods Sold (Q: Apr. 2026 )*Days in Period
=0/0*365 / 4
=

2. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

Anixa Biosciences's Inventory to Revenue for the quarter that ended in Apr. 2026 is calculated as

Inventory-to-Revenue=Average Total Inventories (Q: Apr. 2026 ) / Revenue (Q: Apr. 2026 )
=0 / 0
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Usually retailers pile up their inventories at holiday seasons to meet the stronger demand. Therefore, the inventory of a particular quarter of a year should not be used to calculate Inventory Turnover. An average inventory is a better indication.


Anixa Biosciences Inventory Turnover Related Terms


Anixa Biosciences Inventory Turnover Historical Data

* Premium members only.

The historical data trend for Anixa Biosciences's Inventory Turnover can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Anixa Biosciences Inventory Turnover Chart

Anixa Biosciences Annual Data
Trend Oct16 Oct17 Oct18 Oct19 Oct20 Oct21 Oct22 Oct23 Oct24 Oct25
Inventory Turnover
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Anixa Biosciences Quarterly Data
Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24 Apr24 Jul24 Oct24 Jan25 Apr25 Jul25 Oct25 Jan26 Apr26
Inventory Turnover Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
ANIX
27GF Score
Anixa Biosciences Inc ANIX
Inventory Turnover is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Anixa Biosciences Inventory Turnover Calculation

Anixa Biosciences's Inventory Turnover for the fiscal year that ended in Oct. 2025 is calculated as

Inventory Turnover (A: Oct. 2025 )
=Cost of Goods Sold / Average Total Inventories
=Cost of Goods Sold (A: Oct. 2025 ) / ((Total Inventories (A: Oct. 2024 ) + Total Inventories (A: Oct. 2025 )) / count )
=0 / ((0 + 0) / 1 )
=0 / 0
=N/A

Anixa Biosciences's Inventory Turnover for the quarter that ended in Apr. 2026 is calculated as

Inventory Turnover (Q: Apr. 2026 )
=Cost of Goods Sold / Average Total Inventories
=Cost of Goods Sold (Q: Apr. 2026 ) / ((Total Inventories (Q: Jan. 2026 ) + Total Inventories (Q: Apr. 2026 )) / count )
=0 / ((0 + 0) / 1 )
=0 / 0
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Inventory Turnover →
What does a Inventory Turnover of 0.00 mean?
Anixa Biosciences (ANIX) has a Inventory Turnover of 0.00 as of Apr. 2026. Inventory turnover equals current-period cost of goods sold divided by average two-period total inventories. View historical data on Anixa Biosciences and its competitors.
Is Anixa Biosciences' Inventory Turnover too high?
Anixa Biosciences' current Inventory Turnover is 0.00. Overall, Anixa Biosciences has a GF Score™ of 27/100, reflecting its overall financial health beyond just this single metric.
How does Anixa Biosciences' Inventory Turnover compare to BMEA and PMN?
Anixa Biosciences' Inventory Turnover of 0.00 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Inventory Turnover for a Biotechnology company?
A good Inventory Turnover depends on the Biotechnology industry context. However, Inventory Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Inventory Turnover mean?
A high Inventory Turnover can signal that a stock is expensive relative to its fundamentals. Inventory turnover equals current-period cost of goods sold divided by average two-period total inventories. View historical data on Anixa Biosciences and its competitors. Anixa Biosciences's current Inventory Turnover is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Anixa Biosciences stock overvalued right now?
Anixa Biosciences (ANIX) has a current Inventory Turnover of 0.00. The current Inventory Turnover is 0.00. Anixa Biosciences' overall GF Score™ is 27/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Inventory Turnover calculated?
Inventory Turnover is calculated from a company's financial statements. For Anixa Biosciences (ANIX), the current Inventory Turnover is 0.00 as of Apr. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Anixa Biosciences Business Description

Other Exchanges CY71:Germany
Address 3150 Almaden Expressway, Suite 250, San Jose, CA, USA, 95118
Anixa Biosciences Inc is a biotechnology company developing therapies and vaccines focused on critical unmet needs in oncology. Its operations are organized into reportable segments comprising Cancer Vaccines, CAR-T Therapies, and Other. The Cancer Vaccines segment involves vaccines to treat and prevent breast and ovarian cancer, as well as additional cancer vaccines targeting intractable cancers, including high-incidence malignancies in lung, colon, and prostate. The CAR-T Therapies segment involves the development of liraltagene autoleucel (lira-cel), an ovarian cancer immunotherapy using chimeric endocrine receptor-T cell technology, developed at its subsidiary, Certainty Therapeutics, Inc. The Other segment consists of legacy operations, including limited patent licensing activities.
27GF Score

Get the complete analysis for ANIX

Inventory Turnover is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.81
Price